Neuropathic Pain Market by Drug Class (Tricyclic Anti-Depressants, Anticonvulsants, SNRI's, Capsacin Cream, Local Anaesthesia, Opioids & Steroids)
Industry: Healthcare
Published Date: March-2023
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 182
Report ID: PMRREP4149
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Disease epidemiology
4.2. Product Adoption/ Usage Analysis by region
4.3. Recent Product Approval & Launches
4.4. Regulatory Scenario
4.5. Pipeline Assessment
4.6. PESTLE Analysis
4.7. Porter’s Analysis
4.8. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Pharmaceutical Spending Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Development of Novel Products
5.2.2. Regulatory Approval by Governing Bodies
5.2.3. Increasing Spending on Research and Development
5.2.4. Increasing Neuropathic Pain in Among Population
5.2.5. Rising Number of the Pain Management Centers
5.2.6. Growing Investment by Government Bodies
5.2.7. Strategic Mergers and Acquisitions by Manufacturers
5.2.8. Pipeline Products
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Drug Class
6.1.2. By Indication
6.1.3. By Distribution Channel
6.1.4. By Region
6.2. 2022 Market Scenario
7. Global Market Demand (in Value US$ Mn) Analysis 2013-2022 and Forecast, 2023-2033
7.1. Historical Market Value (US$ Mn) Analysis, 2013-2022
7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2013-2022 and Forecast 2023-2033, By Drug Class
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis, by Drug Class, 2013-2022
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Drug Class, 2023-2033
8.4. Instrument
8.4.1. Tricyclic Anti-Depressants
8.4.2. Anticonvulsants
8.4.3. SNRI's
8.4.4. Capsacin Cream
8.4.5. Local Anaesthesia
8.4.6. Opioids
8.4.7. Steroids
8.4.8. Others
8.5. Market Attractiveness Analysis, by Drug Class
9. Global Market Analysis 2013-2022 and Forecast 2023-2033, By Indication
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2013-2022
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Indication, 2023-2033
9.3.1. Diabetic Neuropathy
9.3.2. Trigeminal Neuralgia
9.3.3. Post-Herpetic Neuralgia
9.3.4. Chemotherapy-Induced Peripheral Neuropathy
9.3.5. Others
9.4. Market Attractiveness Analysis, by Indication
10. Global Market Analysis 2013-2022 and Forecast 2023-2033, By Distribution Channel
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2013-2022
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Distribution Channel, 2023-2033
10.3.1. Retail Pharmacies
10.3.2. Hospital Pharmacies
10.3.3. Online Pharmacies
10.4. Market Attractiveness Analysis, by Distribution Channel
11. Global Market Analysis 2013-2022 and Forecast 2023-2033, By Region
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis, by Region, 2013-2022
11.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Region, 2023-2033
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis, by Region
12. North America Market Analysis 2013-2022 and Forecast 2023-2033
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
12.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
12.3.1. By Country
12.3.1.1. U.S.
12.3.1.2. Canada
12.3.2. By Drug Class
12.3.3. By Indication
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Drug Class
12.4.3. By Indication
12.4.4. By Distribution Channel
12.5. Market Trends
12.6. Key Market Participants – Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. U.S. Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast, by Market Taxonomy
12.8.1.2.1. By Drug Class
12.8.1.2.2. By Indication
12.8.1.2.3. By Distribution Channel
12.8.2. Canada Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast, by Market Taxonomy
12.8.2.2.1. By Drug Class
12.8.2.2.2. By Indication
12.8.2.2.3. By Distribution Channel
13. Latin America Market Analysis 2013-2022 and Forecast 2023-2033
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
13.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
13.3.1. By Country
13.3.1.1. Mexico
13.3.1.2. Brazil
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Drug Class
13.3.3. By Indication
13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Class
13.4.3. By Indication
13.4.4. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants – Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Mexico Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast, by Market Taxonomy
13.8.1.2.1. By Drug Class
13.8.1.2.2. By Indication
13.8.1.2.3. By Distribution Channel
13.8.2. Brazil Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast, by Market Taxonomy
13.8.2.2.1. By Drug Class
13.8.2.2.2. By Indication
13.8.2.2.3. By Distribution Channel
13.8.3. Argentina Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast, by Market Taxonomy
13.8.3.2.1. By Drug Class
13.8.3.2.2. By Indication
13.8.3.2.3. By Distribution Channel
14. Europe Market Analysis 2013-2022 and Forecast 2023-2033
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
14.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. U.K.
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Russia
14.3.1.8. Rest of Europe
14.3.2. By Drug Class
14.3.3. By Indication
14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Class
14.4.3. By Indication
14.4.4. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants – Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Germany Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast, by Market Taxonomy
14.8.1.2.1. By Drug Class
14.8.1.2.2. By Indication
14.8.1.2.3. By Distribution Channel
14.8.2. Italy Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast, by Market Taxonomy
14.8.2.2.1. By Drug Class
14.8.2.2.2. By Indication
14.8.2.2.3. By Distribution Channel
14.8.3. France Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast, by Market Taxonomy
14.8.3.2.1. By Drug Class
14.8.3.2.2. By Indication
14.8.3.2.3. By Distribution Channel
14.8.4. U.K. Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast, by Market Taxonomy
14.8.4.2.1. By Drug Class
14.8.4.2.2. By Indication
14.8.4.2.3. By Distribution Channel
14.8.5. Spain Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast, by Market Taxonomy
14.8.5.2.1. By Drug Class
14.8.5.2.2. By Indication
14.8.5.2.3. By Distribution Channel
14.8.6. BENELUX Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast, by Market Taxonomy
14.8.6.2.1. By Drug Class
14.8.6.2.2. By Indication
14.8.6.2.3. By Distribution Channel
14.8.7. Russia Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast, by Market Taxonomy
14.8.7.2.1. By Drug Class
14.8.7.2.2. By Indication
14.8.7.2.3. By Distribution Channel
15. East Asia Market Analysis 2013-2022 and Forecast 2023-2033
15.1. Introduction
15.2. Historical Market End User (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
15.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Drug Class
15.3.3. By Indication
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Drug Class
15.4.2. By Indication
15.4.3. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants – Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. China Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast, by Market Taxonomy
15.8.1.2.1. By Drug Class
15.8.1.2.2. By Indication
15.8.1.2.3. By Distribution Channel
15.8.2. Japan Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast, by Market Taxonomy
15.8.2.2.1. By Drug Class
15.8.2.2.2. By Indication
15.8.2.2.3. By Distribution Channel
15.8.3. South Korea Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast, by Market Taxonomy
15.8.3.2.1. By Drug Class
15.8.3.2.2. By Indication
15.8.3.2.3. By Distribution Channel
16. South Asia Market Analysis 2013-2022 and Forecast 2023-2033
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
16.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Thailand
16.3.1.5. Rest of South Asia
16.3.2. By Drug Class
16.3.3. By Indication
16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Class
16.4.3. By Indication
16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants – Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast, by Market Taxonomy
16.8.1.2.1. By Drug Class
16.8.1.2.2. By Indication
16.8.1.2.3. By Distribution Channel
16.8.2. Indonesia Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast, by Market Taxonomy
16.8.2.2.1. By Drug Class
16.8.2.2.2. By Indication
16.8.2.2.3. By Distribution Channel
16.8.3. Malaysia Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast, by Market Taxonomy
16.8.3.2.1. By Drug Class
16.8.3.2.2. By Indication
16.8.3.2.3. By Distribution Channel
16.8.4. Thailand Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast, by Market Taxonomy
16.8.4.2.1. By Drug Class
16.8.4.2.2. By Indication
16.8.4.2.3. By Distribution Channel
17. Oceania Market Analysis 2013-2022 and Forecast 2023-2033
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
17.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Drug Class
17.3.3. By Indication
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Class
17.4.3. By Indication
17.4.4. By Distribution Channel
17.5. Key Market Participants - Intensity Mapping
17.6. Key Market Participants – Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Australia Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast, by Market Taxonomy
17.8.1.2.1. By Drug Class
17.8.1.2.2. By Indication
17.8.1.2.3. By Distribution Channel
17.8.2. New Zealand Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast, by Market Taxonomy
17.8.2.2.1. By Drug Class
17.8.2.2.2. By Indication
17.8.2.2.3. By Distribution Channel
18. Middle East and Africa (MEA) Market Analysis 2013-2022 and Forecast 2023-2033
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis, by Market Taxonomy, 2013-2022
18.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, by Market Taxonomy, 2023-2033
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Türkiye
18.3.1.3. South Africa
18.3.1.4. North Africa
18.3.1.5. Rest of Middle East and Africa
18.3.2. By Drug Class
18.3.3. By Indication
18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Drug Class
18.4.2. By Indication
18.4.3. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants – Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. GCC Countries Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast, by Market Taxonomy
18.8.1.2.1. By Drug Class
18.8.1.2.2. By Indication
18.8.1.2.3. By Distribution Channel
18.8.2. Türkiye Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast, by Market Taxonomy
18.8.2.2.1. By Drug Class
18.8.2.2.2. By Indication
18.8.2.2.3. By Distribution Channel
18.8.3. South Africa Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast, by Market Taxonomy
18.8.3.2.1. By Drug Class
18.8.3.2.2. By Indication
18.8.3.2.3. By Distribution Channel
18.8.4. North Africa Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast, by Market Taxonomy
18.8.4.2.1. By Drug Class
18.8.4.2.2. By Indication
18.8.4.2.3. By Distribution Channel
19. Market Structure Analysis
19.1. Market Analysis, by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis
19.3.1. Regional footprint of Players
19.3.2. Channel footprint by Players
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Key Development Analysis
20.4. Branding and Promotional Strategies by Manufacturers
20.5. Competition Deep Dive
20.5.1. Pfizer Inc.
20.5.1.1. Overview
20.5.1.2. Product Portfolio
20.5.1.3. Sales Footprint
20.5.1.4. Key Financials
20.5.1.5. SWOT Analysis
20.5.1.6. Strategy Overview
20.5.1.6.1. Marketing Strategy
20.5.1.6.2. Product Strategy
20.5.1.6.3. Channel Strategy
20.5.2. Johnson & Johnson Services, Inc
20.5.2.1. Overview
20.5.2.2. Product Portfolio
20.5.2.3. Sales Footprint
20.5.2.4. Key Financials
20.5.2.5. SWOT Analysis
20.5.2.6. Strategy Overview
20.5.2.6.1. Marketing Strategy
20.5.2.6.2. Product Strategy
20.5.2.6.3. Channel Strategy
20.5.3. Bristol-Myers Squibb Company
20.5.3.1. Overview
20.5.3.2. Product Portfolio
20.5.3.3. Sales Footprint
20.5.3.4. Key Financials
20.5.3.5. SWOT Analysis
20.5.3.6. Strategy Overview
20.5.3.6.1. Marketing Strategy
20.5.3.6.2. Product Strategy
20.5.3.6.3. Channel Strategy
20.5.4. Sanofi S.A
20.5.4.1. Overview
20.5.4.2. Product Portfolio
20.5.4.3. Sales Footprint
20.5.4.4. Key Financials
20.5.4.5. SWOT Analysis
20.5.4.6. Strategy Overview
20.5.4.6.1. Marketing Strategy
20.5.4.6.2. Product Strategy
20.5.4.6.3. Channel Strategy
20.5.5. Glaxosmithkline plc
20.5.5.1. Overview
20.5.5.2. Product Portfolio
20.5.5.3. Sales Footprint
20.5.5.4. Key Financials
20.5.5.5. SWOT Analysis
20.5.5.6. Strategy Overview
20.5.5.6.1. Marketing Strategy
20.5.5.6.2. Product Strategy
20.5.5.6.3. Channel Strategy
20.5.6. Eli Lilly and Company
20.5.6.1. Overview
20.5.6.2. Product Portfolio
20.5.6.3. Sales Footprint
20.5.6.4. Key Financials
20.5.6.5. SWOT Analysis
20.5.6.6. Strategy Overview
20.5.6.6.1. Marketing Strategy
20.5.6.6.2. Product Strategy
20.5.6.6.3. Channel Strategy
20.5.7. Teva Pharmaceutical Industries Ltd
20.5.7.1. Overview
20.5.7.2. Product Portfolio
20.5.7.3. Sales Footprint
20.5.7.4. Key Financials
20.5.7.5. SWOT Analysis
20.5.7.6. Strategy Overview
20.5.7.6.1. Marketing Strategy
20.5.7.6.2. Product Strategy
20.5.7.6.3. Channel Strategy
20.5.8. Baxter International Inc
20.5.8.1. Overview
20.5.8.2. Product Portfolio
20.5.8.3. Sales Footprint
20.5.8.4. Key Financials
20.5.8.5. SWOT Analysis
20.5.8.6. Strategy Overview
20.5.8.6.1. Marketing Strategy
20.5.8.6.2. Product Strategy
20.5.8.6.3. Channel Strategy
21. Assumptions and Acronyms Used
22. Research Methodology
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Table 01: Global Neuropathic Pain Market Analysis 2013–2022 and Forecast 2023–2033, by Drug Class
Table 02: Global Neuropathic Pain Market Analysis 2013–2022 and Forecast 2023–2033, by Indications
Table 03: Global Neuropathic Pain Market Analysis 2013–2022 and Forecast 2023–2033, by Distribution Channel
Table 04: Global Neuropathic Pain Market Analysis 2013–2022 and Forecast 2023–2033, by Region
Table 05: North America Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Country
Table 06: North America Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Drug Class
Table 07: North America Neuropathic Pain Market Analysis 2013–2022 and Forecast 2023–2033by Indications
Table 08: North America Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Distribution Channel
Table 09: Latin America Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Country
Table 10: Latin America Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Drug Class
Table 11: Latin America Neuropathic Pain Market Analysis 2013–2022 and Forecast 2023–2033by Indications
Table 12: Latin America Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Distribution Channel
Table 13: Europe Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Country
Table 14: Europe Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Drug Class
Table 15: Europe Neuropathic Pain Market Analysis 2013–2022 and Forecast 2023–2033by Indications
Table 16: Europe Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Distribution Channel
Table 17: East Asia Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Country
Table 18: East Asia Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Drug Class
Table 19: East Asia Neuropathic Pain Market Analysis 2013–2022 and Forecast 2023–2033by Indications
Table 20: East Asia Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Distribution Channel
Table 21: South Asia Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Country
Table 22: South Asia Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Drug Class
Table 23: South Asia Neuropathic Pain Market Analysis 2013–2022 and Forecast 2023–2033by Indications
Table 24: South Asia Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Distribution Channel
Table 25: Oceania Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Country
Table 26: Oceania Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Drug Class
Table 27: Oceania Neuropathic Pain Market Analysis 2013–2022 and Forecast 2023–2033by Indications
Table 28: Oceania Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Distribution Channel
Table 29: Middle East & Africa Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Country
Table 30: Middle East & Africa Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Drug Class
Table 31: Middle East & Africa Neuropathic Pain Market Analysis 2013–2022 and Forecast 2023–2033by Indications
Table 32: Middle East & Africa Neuropathic Pain Market Value (US$ Mn) Analysis 2013–2022 and Forecast 2023–2033, by Distribution Channel
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
Figure 01: Global Neuropathic Pain Market Value (US$ Mn) Analysis, 2013–2022
Figure 02: Global Neuropathic Pain Market Forecast & Y-o-Y Growth, 2023–2033
Figure 03: Global Neuropathic Pain Market Absolute $ Opportunity (US$ Mn) Analysis, 2022–2033
Figure 04: Global Neuropathic Pain Market Value Share (%) Analysis 2023 and 2033, by Drug Class
Figure 05: Global Neuropathic Pain Market Y-o-Y Growth (%) Analysis 2022-2033, by Drug Class
Figure 06: Global Neuropathic Pain Market Attractiveness Analysis 2023–2033, by Drug Class
Figure 07: Global Neuropathic Pain Market Value Share (%) Analysis 2023 and 2033, by Indications
Figure 08: Global Neuropathic Pain Market Y-o-Y Growth (%) Analysis 2022-2033, by Indications
Figure 09: Global Neuropathic Pain Market Attractiveness Analysis 2023–2033, by Indications
Figure 10: Global Neuropathic Pain Market Value Share (%) Analysis 2023 and 2033, by Distribution Channel
Figure 11: Global Neuropathic Pain Market Y-o-Y Growth (%) Analysis 2022-2033, by Distribution Channel
Figure 12: Global Neuropathic Pain Market Attractiveness Analysis 2023–2033, by Distribution Channel
Figure 13: Global Neuropathic Pain Market Value Share (%) Analysis 2023 and 2033, by Region
Figure 14: Global Neuropathic Pain Market Y-o-Y Growth (%) Analysis 2022-2033, by Region
Figure 15: Global Neuropathic Pain Market Attractiveness Analysis 2023–2033, by Region
Figure 16: North America Neuropathic Pain Market Size (US$ Mn) Analysis, 2023E & 2033F
Figure 17: North America Neuropathic Pain Market Y-o-Y Analysis, 2023-2033
Figure 18: North America Neuropathic Pain Market Value (US$ Mn) Analysis, 2013–2022
Figure 19: North America Neuropathic Pain Market Value (US$ Mn) Forecast, 2023-2033
Figure 20: North America Neuropathic Pain Market Value Share, by Drug Class (2023 E)
Figure 21: North America Neuropathic Pain Market Value Share, by Indications (2023 E)
Figure 22: North America Neuropathic Pain Market Value Share, by Distribution Channel (2023 E)
Figure 23: North America Neuropathic Pain Market Value Share, by Country (2023 E)
Figure 24: North America Neuropathic Pain Market Attractiveness Analysis by Drug Class, 2023–2033
Figure 25: North America Neuropathic Pain Market Attractiveness Analysis by Indications, 2023–2033
Figure 26: North America Neuropathic Pain Market Attractiveness Analysis by Distribution Channel, 2023–2033
Figure 27: North America Neuropathic Pain Market Attractiveness Analysis by Country, 2023–2033
Figure 28: U.S. Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 29: U.S. Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 30: U.S. Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 31: U.S. Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 32: Global Vs. U.S. Growth Comparison
Figure 33: Canada Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 34: Canada Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 35: Canada Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 36: Canada Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 37: Global Vs. Canada. Growth Comparison
Figure 38: Latin America Neuropathic Pain Market Size (US$ Mn) Analysis, 2023E & 2033F
Figure 39: Latin America Neuropathic Pain Market Y-o-Y Analysis, 2023-2033
Figure 40: Latin America Neuropathic Pain Market Value (US$ Mn) Analysis, 2013–2022
Figure 41: Latin America Neuropathic Pain Market Value (US$ Mn) Forecast, 2023-2033
Figure 42: Latin America Neuropathic Pain Market Value Share, by Drug Class (2023 E)
Figure 43: Latin America Neuropathic Pain Market Value Share, by Indications (2023 E)
Figure 44: Latin America Neuropathic Pain Market Value Share, by Distribution Channel (2023 E)
Figure 45: Latin America Neuropathic Pain Market Value Share, by Country (2023 E)
Figure 46: Latin America Neuropathic Pain Market Attractiveness Analysis by Drug Class, 2023–2033
Figure 47: Latin America Neuropathic Pain Market Attractiveness Analysis by Indications, 2023–2033
Figure 48: Latin America Neuropathic Pain Market Attractiveness Analysis by Distribution Channel, 2023–2033
Figure 49: Latin America Neuropathic Pain Market Attractiveness Analysis by Country, 2023–2033
Figure 50: Mexico Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 51: Mexico Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 52: Mexico Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 53: Mexico Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 54: Global Vs Mexico Growth Comparison
Figure 55: Brazil Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 56: Brazil Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 57: Brazil Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 58: Brazil Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 59: Global Vs. Brazil. Growth Comparison
Figure 60: Argentina Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 61: Argentina Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 62: Argentina Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 63: Argentina Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 64: Global Vs Argentina Growth Comparison
Figure 65: Europe Neuropathic Pain Market Size (US$ Mn) Analysis, 2023E & 2033F
Figure 66: Europe Neuropathic Pain Market Y-o-Y Analysis, 2023-2033
Figure 67: Europe Neuropathic Pain Market Value (US$ Mn) Analysis, 2013–2022
Figure 68: Europe Neuropathic Pain Market Value (US$ Mn) Forecast, 2023-2033
Figure 69: Europe Neuropathic Pain Market Value Share, by Drug Class (2023 E)
Figure 70: Europe Neuropathic Pain Market Value Share, by Indications (2023 E)
Figure 71: Europe Neuropathic Pain Market Value Share, by Distribution Channel (2023 E)
Figure 72: Europe Neuropathic Pain Market Value Share, by Country (2023 E)
Figure 73: Europe Neuropathic Pain Market Attractiveness Analysis by Drug Class, 2023–2033
Figure 74: Europe Neuropathic Pain Market Attractiveness Analysis by Indications, 2023–2033
Figure 75: Europe Neuropathic Pain Market Attractiveness Analysis by Distribution Channel, 2023–2033
Figure 76: Europe Neuropathic Pain Market Attractiveness Analysis by Country, 2023–2033
Figure 77: U.K. Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 78: U.K. Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 79: U.K. Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 80: U.K. Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 81: Global Vs. U.K. Growth Comparison
Figure 82: Germany Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 83: Germany Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 84: Germany Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 85: Germany Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 86: Global Vs. Germany Growth Comparison
Figure 87: Italy Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 88: Italy Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 89: Italy Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 90: Italy Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 91: Global Vs. Italy Growth Comparison
Figure 92: France Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 93: France Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 94: France Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 95: France Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 96: Global Vs France Growth Comparison
Figure 97: Spain Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 98: Spain Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 99: Spain Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 100: Spain Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 101: Global Vs Spain Growth Comparison
Figure 102: Russia Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 103: Russia Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 104: Russia Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 105: Russia Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 106: Global Vs Russia Growth Comparison
Figure 107: BENELUX Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 108: BENELUX Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 109: BENELUX Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 110: BENELUX Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 111: Global Vs BENELUX Growth Comparison
Figure 112: East Asia Neuropathic Pain Market Size (US$ Mn) Analysis, 2023E & 2033F
Figure 113: East Asia Neuropathic Pain Market Y-o-Y Analysis, 2023-2033
Figure 114: East Asia Neuropathic Pain Market Value (US$ Mn) Analysis, 2013–2022
Figure 115: East Asia Neuropathic Pain Market Value (US$ Mn) Forecast, 2023-2033
Figure 116: East Asia Neuropathic Pain Market Value Share, by Drug Class (2023 E)
Figure 117: East Asia Neuropathic Pain Market Value Share, by Indications (2023 E)
Figure 118: East Asia Neuropathic Pain Market Value Share, by Distribution Channel (2023 E)
Figure 119: East Asia Neuropathic Pain Market Value Share, by Country (2023 E)
Figure 120: East Asia Neuropathic Pain Market Attractiveness Analysis by Drug Class, 2023–2033
Figure 121: East Asia Neuropathic Pain Market Attractiveness Analysis by Indications, 2023–2033
Figure 122: East Asia Neuropathic Pain Market Attractiveness Analysis by Distribution Channel, 2023–2033
Figure 123: East Asia Neuropathic Pain Market Attractiveness Analysis by Country, 2023–2033
Figure 124: China Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 125: China Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 126: China Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 127: China Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 128: Global Vs. China Growth Comparison
Figure 129: Japan Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 130: Japan Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 131: Japan Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 132: Japan Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 133: Global Vs. Japan Growth Comparison
Figure 134: South Korea Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 135: South Korea Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 136: South Korea Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 137: South Korea Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 138: Global Vs South Korea Growth Comparison
Figure 139: South Asia Neuropathic Pain Market Size (US$ Mn) Analysis, 2023E & 2033F
Figure 140: South Asia Neuropathic Pain Market Y-o-Y Analysis, 2023-2033
Figure 141: South Asia Neuropathic Pain Market Value (US$ Mn) Analysis, 2013–2022
Figure 142: South Asia Neuropathic Pain Market Value (US$ Mn) Forecast, 2023-2033
Figure 143: South Asia Neuropathic Pain Market Value Share, by Drug Class (2023 E)
Figure 144: South Asia Neuropathic Pain Market Value Share, by Indications (2023 E)
Figure 145: South Asia Neuropathic Pain Market Value Share, by Distribution Channel (2023 E)
Figure 146: South Asia Neuropathic Pain Market Value Share, by Country (2023 E)
Figure 147: South Asia Neuropathic Pain Market Attractiveness Analysis by Drug Class, 2023–2033
Figure 148: South Asia Neuropathic Pain Market Attractiveness Analysis by Indications, 2023–2033
Figure 149: South Asia Neuropathic Pain Market Attractiveness Analysis by Distribution Channel, 2023–2033
Figure 150: South Asia Neuropathic Pain Market Attractiveness Analysis by Country, 2023–2033
Figure 151: India Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 152: India Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 153: India Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 154: India Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 155: Global Vs. India Growth Comparison
Figure 156: Indonesia Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 157: Indonesia Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 158: Indonesia Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 159: Indonesia Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 160: Global Vs. Indonesia Growth Comparison
Figure 161: Malaysia Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 162: Malaysia Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 163: Malaysia Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 164: Malaysia Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 165: Global Vs. Malaysia Growth Comparison
Figure 166: Thailand Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 167: Thailand Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 168: Thailand Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 169: Thailand Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 170: Global Vs. Thailand Growth Comparison
Figure 171: Oceania Neuropathic Pain Market Size (US$ Mn) Analysis, 2023E & 2033F
Figure 172: Oceania Neuropathic Pain Market Y-o-Y Analysis, 2023-2033
Figure 173: Oceania Neuropathic Pain Market Value (US$ Mn) Analysis, 2013–2022
Figure 174: Oceania Neuropathic Pain Market Value (US$ Mn) Forecast, 2023-2033
Figure 175: Oceania Neuropathic Pain Market Value Share, by Drug Class (2023 E)
Figure 176: Oceania Neuropathic Pain Market Value Share, by Indications (2023 E)
Figure 177: Oceania Neuropathic Pain Market Value Share, by Distribution Channel (2023 E)
Figure 178: Oceania Neuropathic Pain Market Value Share, by Country (2023 E)
Figure 179: Oceania Neuropathic Pain Market Attractiveness Analysis by Drug Class, 2023–2033
Figure 180: Oceania Neuropathic Pain Market Attractiveness Analysis by Indications, 2023–2033
Figure 181: Oceania Neuropathic Pain Market Attractiveness Analysis by Distribution Channel, 2023–2033
Figure 182: Oceania Neuropathic Pain Market Attractiveness Analysis by Country, 2023–2033
Figure 183: Australia Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 184: Australia Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 185: Australia Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 186: Australia Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 187: Global Vs. Australia Growth Comparison
Figure 188: New Zealand Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 189: New Zealand Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 190: New Zealand Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 191: New Zealand Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 192: Global Vs New Zealand Growth Comparison
Figure 193: Middle East & Africa Neuropathic Pain Market Size (US$ Mn) Analysis, 2023E & 2033F
Figure 194: Middle East & Africa Neuropathic Pain Market Y-o-Y Analysis, 2023-2033
Figure 195: Middle East & Africa Neuropathic Pain Market Value (US$ Mn) Analysis, 2013–2022
Figure 196: Middle East & Africa Neuropathic Pain Market Value (US$ Mn) Forecast, 2023-2033
Figure 197: Middle East & Africa Neuropathic Pain Market Value Share, by Drug Class (2023 E)
Figure 198: Middle East & Africa Neuropathic Pain Market Value Share, by Indications (2023 E)
Figure 199: Middle East & Africa Neuropathic Pain Market Value Share, by Distribution Channel (2023 E)
Figure 200: Middle East & Africa Neuropathic Pain Market Value Share, by Country (2023 E)
Figure 201: Middle East & Africa Neuropathic Pain Market Attractiveness Analysis by Drug Class, 2023–2033
Figure 202: Middle East & Africa Neuropathic Pain Market Attractiveness Analysis by Indications, 2023–2033
Figure 203: Middle East & Africa Neuropathic Pain Market Attractiveness Analysis by Distribution Channel, 2023–2033
Figure 204: Middle East & Africa Neuropathic Pain Market Attractiveness Analysis by Country, 2023–2033
Figure 205: GCC Countries Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 206: GCC Countries Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 207: GCC Countries Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 208: GCC Countries Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 209: Global Vs GCC Countries Growth Comparison
Figure 210: Türkiye Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 211: Türkiye Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 212: Türkiye Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 213: Türkiye Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 214: Global Vs. Türkiye Growth Comparison
Figure 215: South Africa Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 216: South Africa Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 217: South Africa Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 218: South Africa Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 219: Global Vs. South Africa Growth Comparison
Figure 220: North Africa Neuropathic Pain Market Value Proportion Analysis, 2022
Figure 221: North Africa Neuropathic Pain Market Share Analysis (%) by Drug Class, 2022 & 2033
Figure 222: North Africa Neuropathic Pain Market Share Analysis (%) by Indications, 2022 & 2033
Figure 223: North Africa Neuropathic Pain Market Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 224: Global Vs North Africa Growth Comparison
